RxDoctor Payments Data

Ikram Farooqi

Geriatric Medicine · Wellesley, MANPI 1285685834

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Smith+Nephew at 57.5% of the total.

$603in general payments, 2019–2025

Across 31 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$346
  • Hartmann USA, Inc.$49
  • Organogenesis Inc.$37
  • Boston Scientific$30
  • Bioventus LLC$30
  • Abbott$25
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$57896%
  • Education$254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$603 in reported general payments places this provider in the 80th percentile of 156 geriatric medicine providers in Massachusetts.

See all geriatric medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$1,260,764
Medicare patients
486
Services billed
4,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.28$13,238
Diphenhydramine Hcl50$2,138
Doxycycline Monohydrate97$959
Betamethasone Dipropionate19$867
Mupirocin96$744
Ciprofloxacin Hcl51$464
Nystatin21$356
Lorazepam11$323
Sodium Chloride0.9 % Sodium Chloride12$193
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$172
Prednisone13$143
Tramadol Hcl20$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$346$13,23828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 geriatric medicine providers in Massachusetts.

Other geriatric medicine in Wellesley

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →